These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 30259689)
1. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689 [TBL] [Abstract][Full Text] [Related]
2. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766 [TBL] [Abstract][Full Text] [Related]
3. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905 [TBL] [Abstract][Full Text] [Related]
5. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. Kim IH; Choi MH; Lee IS; Hong TH; Lee MA BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517 [TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819 [TBL] [Abstract][Full Text] [Related]
9. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer. Matsuo Y; Mitsuyoshi T; Shintani T; Iizuka Y; Mizowaki T J Geriatr Oncol; 2018 Nov; 9(6):589-593. PubMed ID: 29779799 [TBL] [Abstract][Full Text] [Related]
10. Muscle mass and association to quality of life in non-small cell lung cancer patients. Bye A; Sjøblom B; Wentzel-Larsen T; Grønberg BH; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Jordhøy M J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):759-767. PubMed ID: 28493418 [TBL] [Abstract][Full Text] [Related]
11. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil. Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016 [TBL] [Abstract][Full Text] [Related]
12. Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. Katsui K; Ogata T; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S Sci Rep; 2021 Jun; 11(1):11882. PubMed ID: 34088965 [TBL] [Abstract][Full Text] [Related]
13. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403. Matsuo Y; Nagata Y; Wakabayashi M; Ishikura S; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Hiraoka M J Radiat Res; 2021 Sep; 62(5):901-909. PubMed ID: 34350956 [TBL] [Abstract][Full Text] [Related]
14. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. He L; Teng Y; Jin B; Zhao M; Yu P; Hu X; Zhang J; Li S; Gao Y; Liu Y BMC Cancer; 2010 Dec; 10():681. PubMed ID: 21156055 [TBL] [Abstract][Full Text] [Related]
15. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305 [TBL] [Abstract][Full Text] [Related]
16. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906 [TBL] [Abstract][Full Text] [Related]
17. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201 [TBL] [Abstract][Full Text] [Related]
18. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101 [TBL] [Abstract][Full Text] [Related]